Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report

BACKGROUND: Vedolizumab, a newer class of integrin antagonist biological agents, has been applied to treat patients with moderate-to-severe Crohn’s disease (CD) and ulcerative colitis (UC), especially for patients who are refractory to traditional therapies and tumor necrosis factor antagonists. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jie, Liu, Mei-Hong, Gao, Xue, Dong, Chang, Li, Yan-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855246/
https://www.ncbi.nlm.nih.gov/pubmed/35211614
http://dx.doi.org/10.12998/wjcc.v10.i5.1716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855246/
https://www.ncbi.nlm.nih.gov/pubmed/35211614
http://dx.doi.org/10.12998/wjcc.v10.i5.1716

Ejemplares similares